GASTRIC CANCER

BeiGene Announces Positive Findings from Phase 3 Trial of Tislelizumab in Combination with Chemotherapy in First-Line Gastric or Gastroesophageal Junction Cancer

Retrieved on: 
Monday, January 24, 2022
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, FDA, Clinical Trials, Gastric Cancer, Tislelizumab, the Tislelizumab Clinical Program, BeiGene, GASTRIC CANCER, TISLELIZUMAB, THE TISLELIZUMAB CLINICAL PROGRAM, BEIGENE

The safety profile of tislelizumab was consistent with that observed in previous trials, with no new safety signals identified with the addition of chemotherapy.

Key Points: 
  • The safety profile of tislelizumab was consistent with that observed in previous trials, with no new safety signals identified with the addition of chemotherapy.
  • The addition of tislelizumab to chemotherapy significantly extended the overall survival for previously untreated patients with advanced or metastatic gastric or gastroesophageal junction adenocarcinoma whose tumor expressed PD-L1.
  • Secondary endpoints include progression-free survival (PFS), overall response rate (ORR), duration of response (DoR), and safety.
  • BeiGene has initiated or completed 17 potentially registration-enabling clinical trials in China and globally, including 13 Phase 3 trials and four pivotal Phase 2 trials.

Novocure and Zai Lab Announce Last Patient Enrolled in Phase 2 Pilot Trial of Tumor Treating Fields Plus Chemotherapy as First-Line Treatment in Gastric Cancer in China

Retrieved on: 
Monday, October 4, 2021
Oncology, Health, Clinical Trials, General Health, Radiology, Biotechnology, Mortality, Glioblastoma, Clinical trial, Cell death, Microtubule, Oxaliplatin, Degenerative disease, Mitosis, Pancreatic cancer, Risk, Cytoplasm, Annual report, Health, Private Securities Litigation Reform Act, NASDAQ, Overalls, U.S. Securities and Exchange Commission, Cancer, Patient, Neoplasm, XELOX, LinkedIn, Adult, Liver cancer, Stomach, Chromosome, Infection, Toxicity, Twitter, Coronavirus, Alternating electric field therapy, Ovarian cancer, Large-cell lung carcinoma, Cell division, Mesothelioma, Stomach cancer, Fundamental, COVID-19, HIV disease progression rates, Drug development, Survival, Safety, Incidence, Cell, Investment, Forward-looking statement, Capecitabine, Data collection, Skin, Protein, Pharmaceutical industry, Medical imaging, Gastric Cancer, Tumor Treating Fields, Novocure, Zai Lab, GASTRIC CANCER, TUMOR TREATING FIELDS, NOVOCURE, ZAI LAB

This trial, conducted entirely in China, showcases Zais capabilities as we partner with Novocure to expand treatment options for gastric cancer patients in China.

Key Points: 
  • This trial, conducted entirely in China, showcases Zais capabilities as we partner with Novocure to expand treatment options for gastric cancer patients in China.
  • The phase 2 pilot gastric cancer trial of TTFields has enrolled approximately 30 patients in Greater China.
  • We look forward to seeing results from this phase 2 pilot trial with our partner, Zai Lab, and to further exploring the potential of Tumor Treating Fields as a treatment for gastric cancer.
  • Novocure has ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer and ovarian cancer.